Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs ABT 165 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 29 Mar 2018 Planned End Date changed from 11 Feb 2020 to 24 Feb 2020.
- 29 Mar 2018 Planned primary completion date changed from 13 Aug 2019 to 24 Feb 2020.
- 21 Feb 2018 Status changed from not yet recruiting to recruiting.